India, Nov. 10 -- Ocugen, Inc. (OCGN) has entered into an exclusive licensing agreement with Sydney-based Celairis Therapeutics Holdings Pty Ltd. for the commercialization of OCU400, its investigational gene therapy for retinitis pigmentosa (RP), across Australia, New Zealand and ASEAN markets.
OCU400 is an investigational modifier gene therapy designed to address the underlying disease biology of retinitis pigmentosa, a group of inherited retinal disorders that cause progressive vision loss and can lead to blindness.
Under the agreement, Ocugen will receive an upfront license fee and potential development and milestone payments totaling up to $7.1 million.
The arrangement includes $6.1 million associated with the upfront payment and OCU...